🎯 Key Takeaways Summary
- Co-prescribe Pyridoxine (Vitamin B6, 10–50 mg daily) with Isoniazid to prevent peripheral neuropathy, especially in pregnancy, diabetes, malnutrition, chronic kidney disease, and HIV.
- Check visual acuity (Snellen chart) and red-green colour vision (Ishihara plates) before and during Ethambutol therapy.
- Record all anti-TB prescriptions in the mandatory Schedule H1 register and ensure Nikshay portal notification.
1. Foundational Clinical & Scientific Overview
Under India's National Tuberculosis Elimination Programme (NTEP), drug-sensitive pulmonary tuberculosis (DS-TB) is treated for 6 months using weight-band daily Fixed-Dose Combinations (FDCs): a 2-month Intensive Phase of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E) [2HRZE], followed by a 4-month Continuation Phase of Isoniazid, Rifampicin, and Ethambutol [4HRE].
2. Core Mechanisms, Classification & Practical Framework
Mycobacterium tuberculosis exists in distinct metabolic subpopulations within pulmonary cavities, macrophages, and caseous granulomas: rapidly dividing extracellular bacilli (killed rapidly by Bactericidal Isoniazid), semi-dormant bacilli undergoing sporadic metabolic bursts (sterilised by Rifampicin), and intracellular bacilli in acidic phagolysosomes (preferentially killed by Pyrazinamide).
Structured Classification & Practical Examples
- Isoniazid (INH): Prodrug activated by bacterial KatG catalase-peroxidase; inhibits InhA (mycolic acid cell-wall synthesis). Causes peripheral neuropathy via pyridoxine (Vitamin B6) depletion.
- Rifampicin (RIF): Inhibits bacterial DNA-dependent RNA polymerase (rpoB). Potent CYP3A4/2C9/2C19/P-gp inducer; causes harmless orange-red discolouration of urine, sweat, and tears.
- Pyrazinamide (PZA): Converted by pyrazinamidase (pncA) to pyrazinoic acid; causes hyperuricaemia/arthralgia and dose-related hepatotoxicity.
- Ethambutol (EMB): Inhibits arabinosyl transferase (embB); bacteriostatic; causes dose-related retrobulbar optic neuritis (red-green colour blindness and reduced visual acuity).
- MDR/RR-TB BPaLM Regimen: Bedaquiline + Pretomanid + Linezolid + Moxifloxacin (6-month all-oral regimen).
3. Advanced Clinical Pharmacy, Dosing & Indian Regulatory Application
Drug-Induced Liver Injury (DILI) & Antiretroviral Co-Administration: Three first-line anti-TB agents (Pyrazinamide > Isoniazid > Rifampicin) are potentially hepatotoxic. If AST/ALT exceeds 5x Upper Limit of Normal (ULN) asymptomatically, or >= 3x ULN with jaundice/nausea/vomiting, withhold HRZ immediately, bridge with non-hepatotoxic agents (Ethambutol + Fluoroquinolone/Aminoglycoside) if clinically severe, and sequentially rechallenge once transaminases normalise. Because Rifampicin strongly induces UGT1A1 and CYP3A4, patients co-infected with HIV receiving Dolutegravir-based antiretroviral therapy (TLD) require an additional 50 mg dose of Dolutegravir 12 hours after TLD (50 mg BD total).
4. Common Misunderstandings & Pharmacist Safety Safeguards
⚠️ Clinical Pitfall & Safety Note: Common Misunderstanding: Stopping anti-TB therapy when the patient's urine turns bright orange-red. Pharmacists must reassure patients upfront that Rifampicin routinely stains urine, saliva, sweat, and soft contact lenses orange-red, whereas yellowing of the sclera (jaundice) with dark tea-coloured urine and right upper quadrant pain requires urgent liver function testing.
5. Explanatory Visual Pharmacology Diagram (svg-v339-09-antimicrobial-mechanisms-bacterial-cell)
6. Authoritative References & Editorial Traceability
Primary Reference Sources: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) by Tejas Nartam; ICMR Standard Treatment Workflows; NFI & NLEM 2022.
Official Portals: CDSCO • Indian Pharmacopoeia Commission (IPC / NFI) • ICMR • FSSAI • NCBI Bookshelf
Educational Disclaimer: Published for pharmacy education, academic learning, and professional clinical reference. Never self-medicate or alter prescribed treatment without consulting a qualified medical practitioner.